Predicting IL-6 Inhibitor Efficacy in MS via Plasmablast Biomarkers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for predicting the therapeutic effect of interferon beta (IFN-β) in multiple sclerosis (MS) patients are inadequate, leading to unnecessary adverse reactions and treatment challenges, particularly in identifying non-responsive patients before administration.
Innovation Solution
A method using immature plasmablast indicators, specifically measuring the amount of follicular helper T cells and immature plasmablasts in peripheral blood, to predict the efficacy of IL-6 inhibitors in MS patients, allowing for targeted treatment selection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If interferon beta (IFN-β) is administered to predict therapeutic effect, then treatment efficacy can be assessed, but serious adverse reactions and aggravation of latent immune disorders occur
Solution Approach 1:
The invention performs preliminary assessment of plasmablast levels and IL-6 pathway activity before administering IFN-β therapy. By measuring plasmablast frequencies and evaluating IL-6 signaling status in advance, the method predicts which patients are likely to respond therapeutically versus those who will experience adverse reactions, allowing preemptive avoidance of harmful treatments
Solution Approach 2:
The invention introduces plasmablast measurement and IL-6 pathway evaluation as intermediary biomarkers between patient selection and IFN-β administration. These intermediaries serve as predictive indicators that mediate the decision-making process, identifying non-responsive patients before they undergo painful and potentially harmful treatment
2Reliability
If IFN-β administration is continued to assess therapeutic effect, then treatment efficacy can be determined, but treatment time is extended by half a year to 1 year
Solution Approach 1:
The invention performs preliminary biomarker assessment (plasmablast levels, IL-6 pathway status) before treatment begins, enabling early prediction of therapeutic response. This preliminary action replaces the need for lengthy 6-12 month treatment periods required by conventional methods to determine efficacy
Solution Approach 2:
The invention establishes a feedback mechanism using plasmablast measurements and IL-6 pathway evaluation to rapidly assess treatment likelihood. This feedback system provides immediate predictive information about therapeutic response, eliminating the prolonged waiting period inherent in traditional IFN-β assessment protocols
3Ease of operation
If IFN-β self-injection is administered, then treatment can be performed, but painful injection and influenza-like symptoms occur
Solution Approach 1:
The invention performs preliminary identification of non-responsive patients using plasmablast and IL-6 biomarkers before treatment initiation. By predicting lack of efficacy in advance, it prevents subjects from undergoing painful self-injection and influenza-like symptoms that would occur with conventional IFN-β administration
4Reliability
If IFN-β is administered to identify non-responsive patients, then therapeutic effect can be evaluated, but unnecessary adverse reactions occur in non-responsive patients
Solution Approach 1:
The invention performs preliminary screening using plasmablast frequency measurement and IL-6 pathway evaluation to identify non-responsive patients before IFN-β administration. This preliminary action prevents unnecessary exposure to treatment and associated adverse reactions in patients who would not benefit therapeutically
Data Source
Figure 1A~1B
Figure 2A~2D
Figure 3
AI summary
According to the present invention, the therapeutic effect of an IL-6 inhibitor on MS was found to be predictable by using as indicators the amount of plasmablasts and/or the indicator of change in immature plasmablasts (amount of immature plasmablasts or amount of follicular helper T cells) in MS patients with a large amount of plasmablasts. Furthermore, IL-6 inhibitors were found to be effective against MS in which plasmablasts occur at high levels and in which the indicator of change in immature plasmablasts is high. The present invention provides methods for selecting MS cases for which treatment with an IL-6 inhibitor is effective, and also provides an effective therapeutic method for patients with MS in which plasmablast occur at high levels and in which the indicator of change in immature plasmablasts is high.